These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 5536051)

  • 21. [Therapy of parkinsonian syndromes with L-dopa. Results and prospects].
    Fazio C
    Sist Nerv; 1970; 22(2):61-6. PubMed ID: 5504558
    [No Abstract]   [Full Text] [Related]  

  • 22. [On the mode of action and the question of central organic late damages of continuous neuroleptic treatment].
    Haddenbrock S
    Nervenarzt; 1966 May; 37(5):199-203. PubMed ID: 5298253
    [No Abstract]   [Full Text] [Related]  

  • 23. Stimulation of human-growth-hormone secretion by L-dopa.
    Boyd AE; Lebovitz HE; Pfeiffer JB
    N Engl J Med; 1970 Dec; 283(26):1425-9. PubMed ID: 5481776
    [No Abstract]   [Full Text] [Related]  

  • 24. [Present-day possibilities of relieving post-neuroleptic extrapyramidal symptoms].
    Wasik A
    Psychiatr Pol; 1973; 7(1):51-6. PubMed ID: 4715833
    [No Abstract]   [Full Text] [Related]  

  • 25. [The drug-induced Parkinson's syndrome].
    Pakesch E
    Wien Z Nervenheilkd Grenzgeb; 1966; 23(1):140-6. PubMed ID: 4226879
    [No Abstract]   [Full Text] [Related]  

  • 26. [Extrapyramidal complications of psychopharmacological drugs].
    Vacek J
    Cesk Psychiatr; 1969 Dec; 65(6):414-21. PubMed ID: 4983105
    [No Abstract]   [Full Text] [Related]  

  • 27. [Experiences in the treatment of Parkinsonism with L-dopa. IV. Effects on the experimental extrapyranidal brady-akinesia in cats].
    Bergamini L; Bonzanino O; Brignolio F; Fabiani A; Fariello R; Mombelli AM; Mutani R; Pisani W; Postir A; Quattroccolo G; Riccio A; Sabbatini F; Sandigliano G; Schiffer D
    Riv Patol Nerv Ment; 1970 Feb; 91(1):62-6. PubMed ID: 5524934
    [No Abstract]   [Full Text] [Related]  

  • 28. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)].
    Mazza C; Buffatti PF; Bazzan A; Lion P
    Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378
    [No Abstract]   [Full Text] [Related]  

  • 29. L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression.
    Kimura N; Tsukue I
    Hiroshima J Med Sci; 1971 Mar; 20(1):55-63. PubMed ID: 5121129
    [No Abstract]   [Full Text] [Related]  

  • 30. [Action of amantadine in extrapyramidal syndromes caused by neuroleptics].
    Fanali A; Nardini M; Sorgona F
    Sist Nerv; 1970; 22(5):273-85. PubMed ID: 5514245
    [No Abstract]   [Full Text] [Related]  

  • 31. [The semiology of motor function disorders during treatment with neuroleptic drugs].
    Fleĭs EP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(12):1798-804. PubMed ID: 5511943
    [No Abstract]   [Full Text] [Related]  

  • 32. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462
    [No Abstract]   [Full Text] [Related]  

  • 33. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 34. Behavioral effects of l-dopa in man.
    Goodwin FK
    Semin Psychiatry; 1971 Nov; 3(4):477-92. PubMed ID: 5173049
    [No Abstract]   [Full Text] [Related]  

  • 35. [Mental disorders in the course of L-dopa treatment].
    Reichowa J; Goldsztajn M
    Psychiatr Pol; 1973; 7(1):87-9. PubMed ID: 4715838
    [No Abstract]   [Full Text] [Related]  

  • 36. [Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
    Kamianov IM; Kupisk AG; Katsen IZ
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(8):1218-23. PubMed ID: 4149581
    [No Abstract]   [Full Text] [Related]  

  • 37. [Individual predisposition for unusual extrapyramidal side effects with neuroleptic agents].
    Lingjaerde O
    Tidsskr Nor Laegeforen; 1971 May; 91(13):977-9. PubMed ID: 5576970
    [No Abstract]   [Full Text] [Related]  

  • 38. [The therapeutic effect of L-dopa].
    Groneberg P; Struppler A
    Naturwissenschaften; 1972 Nov; 59(11):492-6. PubMed ID: 4657650
    [No Abstract]   [Full Text] [Related]  

  • 39. [Principles of the pathogenetic therapy of congenital extrapyramidal diseases].
    Tkachev RA; Markova ED; Gotovtseva EV; Barkhatova VP; Ivanova-Smolenskaia IA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):513-9. PubMed ID: 4705405
    [No Abstract]   [Full Text] [Related]  

  • 40. [Use of methamidoline in the treatment of parkinson-like manifestations due to neuroleptics].
    Arnone A; Parodi A
    Riv Sper Freniatr Med Leg Alien Ment; 1971 Dec; 95(6):1126-42. PubMed ID: 5143724
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.